Szeged, September 2, 2024 – Novartis Hungária and Goodwill Pharma have entered into a partnership agreement. The primary goal of the partnership is to optimize portfolio strategies, which can contribute to enhancing the security of domestic pharmaceutical supply. In the long term, however, the collaboration between the two companies may extend to a regional level and include research and development.
Novartis Hungária and Goodwill Pharma have entered into an exclusive distribution and promotional partnership.
“One of the cornerstones of our strategy is to build long-term partnerships to address society’s most challenging healthcare issues. Therefore, we are delighted to collaborate with Goodwill Pharma. Our newly launched joint work will help us achieve our goal of ensuring that the right medicines reach patients as quickly as possible and remain available in the long term, and to support Hungarian patient care with ever newer and innovative therapies. The collaboration will also help us focus more on the introduction of innovative therapies in Hungary, increasing our pharmaceutical supply efficiency, while our experienced domestic partner can concentrate on managing the portfolio already introduced and available in the country,” said Colette Matz, CEO of Novartis Hungária, regarding the contract signing.
Dr. Ferenc Jójárt, CEO of Goodwill Pharma, added: “We are proud to welcome Novartis Hungária among our partners. Thanks to the expanded product portfolio, we can enter new therapeutic areas and introduce new products in existing ones. One of the main drivers of our collaboration is to ensure the smooth supply of domestic pharmaceutical players, both wholesale and retail. We expect that this will also result in a more balanced supply for independent Hungarian-owned pharmacies, thanks to our already established extensive network, thereby helping to secure supply.”
The collaboration, starting on September 2, will facilitate the medication supply for hundreds of thousands of Hungarian patients. From September, Goodwill Pharma will take over the domestic distribution and promotion of products for the treatment of chronic obstructive pulmonary disease and two new asthma treatments from Novartis Hungária. According to plans, from January, the Hungarian-owned company will also take over the entire ophthalmic portfolio. The partnership may later expand with additional medicines and, in the long term, may also extend to a regional level and include research and development.
The partnership between Novartis Hungária and Goodwill Pharma combines decades of global expertise with local market knowledge. The knowledge and experience gained through such collaborations can also foster the development of the Hungarian pharmaceutical industry and healthcare sector.
***
About Novartis
Novartis is an innovative pharmaceutical company. Every day, we work to reimagine medicine to improve people’s quality of life and extend their lives, enabling patients, healthcare professionals, and societies to confront serious diseases. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: learn more about us at https://www.novartis.hu and connect with us on LinkedIn.
About Goodwill Pharma
Goodwill Pharma Plc., founded in 1997, is a dynamically growing publicly traded company that has been present in various areas of the pharmaceutical industry with its products and services for the past 27 years. The company’s core business focuses on the development, production, and distribution of pharmaceutical products, primarily in the Central and Eastern European markets. The word “goodwill” represents goodwill, the value of good health, and faith in the future. The company’s goal is to develop and market high-quality, value-driven, and effective therapeutic products in various therapeutic areas. Goodwill Pharma is one of the three pharmaceutical companies listed on the Budapest Stock Exchange and the creator of the Albert Szent-Györgyi product family. Its main research areas include the development of products aimed at extending the healthy lifespan.